Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
WATERTOWN, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced favorable topline results from its Phase 1a clinical trial evaluating TX2100, an investigational VHH-Fc fusion antagonist antibody targeting the APJ (apelin) receptor, in healthy adult volunteers. The clinical trial was designed to support the advancement of clinical development for TX2100 as a potential treatment for Hereditary Hemorrhagic Telangiectasia (HHT), a rare, inherited vascular disorder with no currently approved therapies. The Company also announced that the U.S. Food and Drug Administration (FDA) granted TX2100 Fast Track Designation for HHT. In addition, the FDA recently cleared the Company’s Investigational New Drug (IND) application to conduct the upcoming TX2100 Phase 1b clinical trial in the U.S. in patients with HHT.